TRUQAP

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania, Romania, UK.

Active ingredients

The drug TRUQAP contains one active pharmaceutical ingredient (API):

1	Capivasertib UNII WFR23M21IE - CAPIVASERTIB
	Capivasertib is a potent, selective inhibitor of the kinase activity of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3). AKT activation in tumours is a result of upstream activation from other signalling pathways, mutations of AKT1, loss of Phosphatase and Tensin Homolog (PTEN) function and mutations in the catalytic subunit of PI3K (PIK3CA). Capivasertib reduces growth of cell lines derived from solid tumours and haematological disease, including breast cancer cell lines with and without PIK3CA or AKT1 mutations, or PTEN alterations.
	Read more about Capivasertib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRUQAP Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
TRUQAP Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX27		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3081529, 3081530
FR	Base de données publique des médicaments	65968984, 68102912
IT	Agenzia del Farmaco	051358012, 051358024
LT	Valstybinė vaistų kontrolės tarnyba	1100042, 1100043
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70411001, W70412001
US	FDA, National Drug Code	0310-9500, 0310-9501